II-III期非小细胞肺癌患者个体化剂量递增后的患者报告结局:随机ARTFORCE PET-Boost试验结果
国际随机2期ARTFORCE PET-Boost试验纳入107例II-III期非小细胞肺癌患者(102例纳入分析),比较原发肿瘤整体或FDG高摄取亚区个体化剂量递增(24次×3.0-5.4 Gy)后的患者报告结局。线性混合效应模型显示两组总体健康相关生活质量随时间无显著变化、组间无显著差异,尽管呼吸困难、吞咽困难和疲乏等症状频繁报告。
要点
- 两组总体健康相关生活质量随时间无显著变化,组间亦无显著差异。
- 两组躯体功能在治疗期间及18个月随访时逐渐下降。
- 呼吸困难有临床意义的恶化主要见于3个月和6个月时。
核心结论
- 在接受两种剂量递增策略的局部晚期非小细胞肺癌患者中,两组平均患者报告健康相关生活质量保持稳定,尽管呼吸困难、吞咽困难和疲乏等症状频繁报告。
研究设计与样本
- 国际随机2期ARTFORCE PET-Boost试验(NCT01024829),2010年4月至2017年9月随机107例,102例纳入本分析。
- 纳入II-III期非小细胞肺癌且原发肿瘤≥4 cm的患者,治疗为个体化递增分次剂量(24次×3.0-5.4 Gy),照射原发肿瘤整体或其FDG高摄取亚区。
- 患者接受序贯或同步放化疗,或单纯放疗;采用EORTC QLQ-C30、QLQ-LC13和EuroQol-5D在8个时间点评估。
主要发现
- 线性混合效应模型显示总体健康相关生活质量随时间无显著变化,两组间无显著差异。
- 两组躯体功能在治疗期间及18个月随访时逐渐下降。
- 呼吸困难有临床意义的恶化主要见于3个月和6个月时。
- 问卷依从率:基线86.3%,3个月85.3%,12个月80.3%,放疗期间最低为35.0%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The ultimate challenge in dose-escalation trials lies in finding the balance between benefit and toxicity. We examined patient-reported outcomes (PROs), including health-related quality of life (HRQoL) in patients with locally advanced non-small cell lung cancer (LA-NSCLC), treated with dose-escalated radiotherapy. MATERIALS AND METHODS: The international, randomised, phase 2 ARTFORCE PET-Boost study (NCT01024829) aimed to improve 1-year freedom from local failure rates in patients with stage II-III NSCLC, with a ≥ 4 cm primary tumour. Treatment consisted of an individualised, escalated fraction dose, either to the primary tumour as a whole or to its most FDG-avid subvolume (24 x 3.0-5.4 Gy). Patients received sequential or concurrent chemoradiotherapy, or radiotherapy only. Patients were asked to complete the EORTC QLQ-C30, QLQ-LC13, and the EuroQol-5D at eight timepoints. We assessed the effect of dose-escalation on C30 sum score through mixed-modelling and evaluated clinically meaningful changes for all outcomes. RESULTS: Between Apr-2010 and Sep-2017, 107 patients were randomised; 102 were included in the current analysis. Compliance rates: baseline 86.3%, 3-months 85.3%, 12-months 80.3%; lowest during radiation treatment 35.0%. A linear mixed-effect (LME) model revealed no significant change in overall HRQoL over time, and no significant difference between the two treatment groups. Physical functioning showed a gradual decline in both groups during treatment and at 18-months follow-up, while clinically meaningful worsening of dyspnoea was seen mainly at 3- and 6-months. CONCLUSION: In patients with LA-NSCLC treated with two dose-escalation strategies, the average patient-reported HRQoL remained stable in both groups, despite frequent patient-reported symptoms, including dyspnoea, dysphagia, and fatigue.
引用
- Cooke SA, Belderbos JSA, Reymen B, et al. Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial. Radiother Oncol. 2024. PMID: 38663582. doi:10.1016/j.radonc.2024.110312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。